Analysts Turn Bullish on Biohaven, Caris, and Veracyte
Canaccord says Biohaven is undervalued and could rise on epilepsy trial results. Jefferies likes Caris Life Sciences and Veracyte, citing strong growth in cancer diagnostics and solid finances.
/ 9 items
#BHVN↓
Goldman Sachs Starts Coverage on Biohaven with Buy Rating
Goldman Sachs initiates coverage on Biohaven with a Buy rating and $23 price target, highlighting BHV-1400 and its potential in the large IgA nephropathy market.
RBC Capital Turns Bullish on Biohaven: Big Upgrade and Higher Price Target
RBC Capital upgrades Biohaven to Outperform, raises price target to $22, and highlights improving data, lower risk, and strong 2026 catalysts.
BofA Raises Biohaven Price Target to $15 on Pipeline Progress, But Stays Cautious
Bank of America upgrades Biohaven's price target by 50% following positive pipeline updates, but maintains neutral rating citing uncertain 2026 catalysts.
Biohaven's Depression Drug BHV-7000 Falls Short in Clinical Trial
Biohaven's (BHVN) experimental depression treatment BHV-7000 didn't meet its primary goal in Phase 2 testing, though some patient subgroups showed promising trends.
Biohaven's BHV-1510 Shows 100% Response Rate in Endometrial Cancer Trial
Biohaven's (BHVN) BHV-1510 cancer drug shows impressive response rates in lung, endometrial, and bladder cancers with fewer side effects than similar treatments.